Tell us what you think about the new Article Page. Send us feedback
Celldex Therapeutics to Present at Merriman Curhan Ford's Investor Summit 2009
Related Quotes
| Symbol | Price | Change |
|---|---|---|
| CLDX | 4.68 | +0.20 |
NEEDHAM, Mass.--(BUSINESS WIRE)--Celldex Therapeutics, Inc. (Nasdaq: CLDX - News) today announced that Anthony S. Marucci, President and Chief Executive Officer of Celldex Therapeutics, Inc., will present at Merriman Curhan Ford’s 6th Annual Investor Summit at the Sofitel Hotel, New York City on Tuesday, November 10, 2009 at 2:40 pm, EST.
A live webcast of the 15-minute audio presentation will be available online at http://www.wsw.com/webcast/mcm12/cldx/ and on the “Presentations” page of the Investor Information section of Celldex’s website at http://www.celldextherapeutics.com. An archive of the webcast will be available via Celldex’s website for 90 days following the event.
About Celldex Therapeutics, Inc.
Celldex Therapeutics is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex’s immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates. For more information, please visit http://www.celldextherapeutics.com.
About Merriman Curhan Ford
Merriman Curhan Ford (NASDAQ: MERR) is a financial services firm focused on fast-growing companies and the institutions that invest in them. The company offers high-quality investment banking, equity research, institutional services and corporate & venture services, and specializes in five growth industry sectors: CleanTech, Consumer, Media & Internet, Health Care, Natural Resources and Technology. For more information, please go to www.mcfco.com.
Contact:
Celldex Therapeutics, Inc.
Anthony S. Marucci, 781-433-0771
President and CEO
or
Avery W. Catlin, 781-433-0771
Chief Financial Officer
IR@celldextherapeutics.com
or
Celldex Investor Relations:
MacDougall Biomedical Communications
Sarah Cavanaugh, 781-235-3060
scavanaugh@macbiocom.com
or
Celldex Media:
BMC Communications Group
Matthew Driscoll, 212-477-9007 x20
mdriscoll@bmccommunications.com
Related Headlines
- Early-Market Movers: XTO, Geron - at Fox Business
- Celldex Therapeutics Presents Positive Results from Phase 2 Study of the Antibody-Drug Conjugate (ADC) Product Candidate CDX-011 in Advanced Breast Cancer - Business Wire
- Celldex Therapeutics to Present CDX-011 Clinical Data at the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium - Business Wire
- CELLDEX THERAPEUTICS, INC. Financials - EDGAR Online Financials
- CELLDEX THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report - EDGAR Online
Related Blog Headlines
- Mentor Capital Cancer Vaccine Investing Update - at Seeking Alpha
- Mentor Capital Plans 2010 Launch of Cancer Vaccine Active Index Fund - at Seeking Alpha
Top Stories
Tech Ticker Recent Posts
- Obama's Health-Care Reform "Quite Positive" for Big Pharma, Managed Care Stocks - Peter Gorenstein
- Senate Bill: True Health-Care Reform or the End of Capitalism? - Aaron Task
- Macau: It's Just Like Vegas Except Business Is Booming - Peter Gorenstein
Add Alert Copyright © 2009 Business Wire. All rights reserved. All the news releases provided by Business Wire are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials by posting, archiving in a public web site or database, or redistribution in a computer network is strictly forbidden.